Engineering a multi epitope vaccine against SARS-CoV-2 by exploiting its non structural and structural proteins

Area of Science:

• * Virology and Immunology
• * Computational Biology and Bioinformatics
• * Vaccine Development

Background:

• * SARS-CoV-2 poses a significant global health threat, necessitating advanced vaccine strategies.
• * Multi-epitope subunit vaccines offer a promising approach to combat infectious diseases like COVID-19.
• * Previous coronaviruses (SARS-CoV, MERS-CoV) highlight the need for effective countermeasures.

Purpose of the Study:

• * To design and computationally evaluate a novel multi-epitope subunit vaccine candidate against SARS-CoV-2.
• * To identify B and T cell epitopes from SARS-CoV-2 proteins for vaccine development.
• * To assess the safety, stability, and immunogenicity of the proposed vaccine construct.

Main Methods:

• * Immunoinformatics tools were employed to select epitopes from SARS-CoV-2 structural and non-structural proteins.
• * Computational methods were used to evaluate antigenicity, safety, structural stability, and production feasibility.
• * Molecular docking and dynamics simulations assessed binding affinity with human TLR-3, and immune simulation predicted response.

Main Results:

• * A vaccine construct incorporating multiple B and T cell epitopes was successfully designed.
• * Computational analyses confirmed favorable antigenicity, safety, stability, and production potential.
• * Strong and stable binding interactions with human TLR-3 were observed, indicating effective viral sensing.
• * Immune simulation predicted a robust immune response upon vaccine administration.

Conclusions:

• * The proposed multi-epitope subunit vaccine candidate is computationally validated as safe and immunogenic.
• * This vaccine construct shows significant potential as a lead for further in vitro and in vivo studies.
• * Immunoinformatics provides a powerful platform for rapid development of next-generation vaccines against emerging pathogens.